JP2021512921A5 - - Google Patents

Info

Publication number
JP2021512921A5
JP2021512921A5 JP2020542862A JP2020542862A JP2021512921A5 JP 2021512921 A5 JP2021512921 A5 JP 2021512921A5 JP 2020542862 A JP2020542862 A JP 2020542862A JP 2020542862 A JP2020542862 A JP 2020542862A JP 2021512921 A5 JP2021512921 A5 JP 2021512921A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
administered
product according
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512921A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017430 external-priority patent/WO2019157423A1/en
Publication of JP2021512921A publication Critical patent/JP2021512921A/ja
Publication of JP2021512921A5 publication Critical patent/JP2021512921A5/ja
Pending legal-status Critical Current

Links

JP2020542862A 2018-02-12 2019-02-11 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン Pending JP2021512921A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629579P 2018-02-12 2018-02-12
US62/629,579 2018-02-12
PCT/US2019/017430 WO2019157423A1 (en) 2018-02-12 2019-02-11 Methods and dosing regimens using ibudilast and a second agent for cancer therapy

Publications (2)

Publication Number Publication Date
JP2021512921A JP2021512921A (ja) 2021-05-20
JP2021512921A5 true JP2021512921A5 (cg-RX-API-DMAC7.html) 2022-02-17

Family

ID=67542181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542862A Pending JP2021512921A (ja) 2018-02-12 2019-02-11 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン

Country Status (6)

Country Link
US (2) US10744123B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752147A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512921A (cg-RX-API-DMAC7.html)
CN (1) CN112236140A (cg-RX-API-DMAC7.html)
CA (1) CA3090884A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019157423A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090884A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
CN113584172B (zh) * 2021-08-04 2022-08-02 中南大学湘雅二医院 Slc12a5及其抑制剂的应用
CA3231869A1 (en) * 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562198A (en) 1998-08-10 2000-03-06 Kyorin Pharmaceutical Co. Ltd. Remedies for multiple sclerosis
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CN115778934A (zh) * 2012-01-20 2023-03-14 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
US20160361298A1 (en) * 2015-06-11 2016-12-15 Globavir Biosciences, Inc. Methods and compositions for treating cancer
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3090884A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy

Similar Documents

Publication Publication Date Title
CA2856646C (en) Combination treatment of cancer
JP2015512406A5 (cg-RX-API-DMAC7.html)
JP2019131588A5 (ja) 抗そう痒剤
JP2022095882A5 (ja) 医薬組成物
JP2018520189A5 (cg-RX-API-DMAC7.html)
JP2002532392A5 (cg-RX-API-DMAC7.html)
JP2020521797A5 (cg-RX-API-DMAC7.html)
JP2012521355A5 (cg-RX-API-DMAC7.html)
CA3034875C (en) Combination therapies for the treatment of hepatocellular carcinoma
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
CN108939074A (zh) 治疗再生障碍性贫血的方法和药物组合物
JP2023531930A5 (cg-RX-API-DMAC7.html)
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
TW201313229A (zh) 改善自體免疫病如慢性風濕之治療方法
JP2022514561A5 (cg-RX-API-DMAC7.html)
JP2021535163A5 (cg-RX-API-DMAC7.html)
CA2986359A1 (en) Pharmaceutical combination of everolimus with dactolisib
CA2684174C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
AU2007234917B2 (en) Renin inhibitors for the treatment of hypertension
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
JP2021091608A5 (cg-RX-API-DMAC7.html)
JP2022518527A5 (cg-RX-API-DMAC7.html)
JP7267326B2 (ja) 成熟脳損傷の治療における使用のためのmGluR5のネガティブアロステリックモジュレーター
JP2024543347A5 (cg-RX-API-DMAC7.html)
JPWO2024241468A5 (cg-RX-API-DMAC7.html)